CA2842552A1 - Use of the antibody i-3859 for the detection and diagnosis of cancer - Google Patents

Use of the antibody i-3859 for the detection and diagnosis of cancer Download PDF

Info

Publication number
CA2842552A1
CA2842552A1 CA2842552A CA2842552A CA2842552A1 CA 2842552 A1 CA2842552 A1 CA 2842552A1 CA 2842552 A CA2842552 A CA 2842552A CA 2842552 A CA2842552 A CA 2842552A CA 2842552 A1 CA2842552 A1 CA 2842552A1
Authority
CA
Canada
Prior art keywords
cxcr4
sequence seq
antibody
cdr
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2842552A
Other languages
English (en)
French (fr)
Inventor
Christine Klinguer-Hamour
Alexandra Jouhanneaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of CA2842552A1 publication Critical patent/CA2842552A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2842552A 2011-07-29 2012-07-30 Use of the antibody i-3859 for the detection and diagnosis of cancer Abandoned CA2842552A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161513345P 2011-07-29 2011-07-29
US61/513,345 2011-07-29
EP11306000.8 2011-07-29
EP11306000 2011-07-29
PCT/EP2012/064876 WO2013017562A1 (en) 2011-07-29 2012-07-30 Use of the antibody i-3859 for the detection and diagnosis of cancer

Publications (1)

Publication Number Publication Date
CA2842552A1 true CA2842552A1 (en) 2013-02-07

Family

ID=47628653

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2842552A Abandoned CA2842552A1 (en) 2011-07-29 2012-07-30 Use of the antibody i-3859 for the detection and diagnosis of cancer

Country Status (14)

Country Link
US (1) US20140170677A1 (enExample)
EP (1) EP2736926A1 (enExample)
JP (1) JP6138780B2 (enExample)
KR (1) KR20140047127A (enExample)
CN (1) CN103717620A (enExample)
AR (1) AR087363A1 (enExample)
AU (2) AU2012292116A1 (enExample)
BR (1) BR112014001979A2 (enExample)
CA (1) CA2842552A1 (enExample)
IL (1) IL230693A0 (enExample)
MX (1) MX2014001160A (enExample)
RU (1) RU2636032C2 (enExample)
WO (1) WO2013017562A1 (enExample)
ZA (1) ZA201400500B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3316159A4 (en) 2015-06-25 2019-08-14 Advanced Telecommunications Research Institute International PREDICTIVE EQUIPMENT BASED ON A SYSTEM ASSOCIATED WITH SEVERAL INSTITUTIONS AND PREDICTION PROGRAM
EP3365682B1 (en) * 2015-10-23 2020-10-07 Novartis AG System for deriving cell-to-cell spatial proximities
US11357742B2 (en) 2015-12-14 2022-06-14 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN114594268A (zh) 2016-03-29 2022-06-07 无限生物制药公司 用以预防或治疗肾脏疾病的活性组分的候选物质的筛选装置和筛选方法
EP3466446B1 (en) 2016-03-29 2023-12-27 Karydo Therapeutix, Inc. Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
CN111465613A (zh) * 2017-11-07 2020-07-28 X4 制药有限公司 癌症生物标志物及其使用方法
US20210025895A1 (en) * 2018-04-13 2021-01-28 X4 Pharmaceuticals, Inc. Cancer serum biomarkers and methods of use thereof
WO2021183650A1 (en) 2020-03-10 2021-09-16 X4 Pharmaceuticals, Inc. Methods for treating neutropenia

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU766675B2 (en) * 1998-03-30 2003-10-23 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
JP2003532683A (ja) 2000-05-09 2003-11-05 ザ ユニバーシティ オブ ブリティッシュ コロンビア 造血細胞のｃｘｃｒ４アンタゴニスト治療
AU2001275339A1 (en) 2000-06-05 2001-12-17 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
AU2003232253A1 (en) * 2003-05-02 2004-11-23 Polyphor Ag Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
US8329178B2 (en) * 2005-02-18 2012-12-11 Dana-Farber Cancer Institute, Inc. Antibodies against CXCR4 and methods of use thereof
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP2486941B1 (en) * 2006-10-02 2017-03-15 E. R. Squibb & Sons, L.L.C. Human antibodies that bind CXCR4 and uses thereof
EP2172485A1 (en) 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV

Also Published As

Publication number Publication date
AU2012292116A1 (en) 2014-02-06
EP2736926A1 (en) 2014-06-04
MX2014001160A (es) 2014-07-14
RU2014103054A (ru) 2015-09-10
CN103717620A (zh) 2014-04-09
BR112014001979A2 (pt) 2017-02-21
AR087363A1 (es) 2014-03-19
RU2636032C2 (ru) 2017-11-17
ZA201400500B (en) 2014-11-26
AU2017204043A1 (en) 2017-07-06
JP6138780B2 (ja) 2017-05-31
WO2013017562A1 (en) 2013-02-07
JP2014523920A (ja) 2014-09-18
US20140170677A1 (en) 2014-06-19
KR20140047127A (ko) 2014-04-21
IL230693A0 (en) 2014-03-31

Similar Documents

Publication Publication Date Title
US9518120B2 (en) Anti-CXCR4 antibody and its use for the detection and diagnosis of cancer
JP6138780B2 (ja) 癌の検出および診断のための抗体ｉ−３８５９の使用
CA2794407C (en) Humanized anti cxcr4 antibodies for the treatment of cancer
US20210018508A1 (en) Igf-1r antibody and its use for the diagnosis of cancer
CA2983071C (en) Igf-1r antibody and its use for the diagnosis of cancer
TW201311726A (zh) 抗體ｉ－３８５９用於癌症偵測及診斷之用途
OA18453A (en) IGF-1R antibody and its use for the diagnosis of cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170718

FZDE Discontinued

Effective date: 20190730